Clinical nutrition and longevity biotech company advances commercialization of patented postbiotic strain D3.5 and prepares launch of Gutibio™ medical food in April 2026
WINSTON-SALEM, NC, February 9, 2026 (Newswire.com)
–
Postbiotics, Inc. (PBI), a clinical nutrition, longevity and biotechnology start-up targeting gut-brain support, age‑related disease, and clinical microbiome innovations, today announces a strategic investment from Wake Forest University School of Medicine.
PBI develops non-pharmaceutical, therapeutic solutions, for extending healthspan, and has an exclusive, world-wide license from Wake Forest University, for heat‑stable Lacticaseibacillus paracasei strain D3.5. This patented postbiotic strain has been shown in mechanism and human studies to increase lifespan, healthspan, and regenerate the mucus layer of the gut.
PBI’s PoZibio®, is a proprietary gut health ingredient for use in foods, beverages, and dietary supplements. The company’s latest D3.5 product is Gutibio™, a medical food supervised by physicians and clinically studied in humans. Gutibio™ launches in April 2026, and targets nutritional deficiencies associated with gut health diseases/chronic conditions such as Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). Gutibio™ is formulated to better manage nutritional needs associated with potentially life‑long complications that can develop as a result of chemotherapy and radiation treatments.
“Wake Forest University School of Medicine is pleased to extend our exclusive license agreement with Postbiotics, Inc. for the patent-approved postbiotic strain D3.5, with an equity position in PBI” said John Druga, Director of New Business Opportunities, Wake Forest Innovations. Druga continued, “We believe that Postbiotics brings credible expertise for commercial success in the clinical nutrition space by advancing the science developed at Wake Forest University.”
“Deepening our relationship with Wake Forest University School of Medicine validates applications for medical foods, adds depth and capability to the PBI team, and accelerates sales through faster implementation of strategic business plans” said Robert Anderson, Co‑founder and CEO of PBI. “We welcome investors to participate in our passion to positively impact human health and longevity.”
About Postbiotics, Inc.
Postbiotics, Inc. (PBI) is a commercial-ready longevity and biotech company developing non-prescription, scientifically validated therapeutic products from postbiotics, addressing age-related conditions. PBI’s first products are based on a proprietary heat-treated Lacticaseibacillus paracasei strain (D3.5) discovered at Wake Forest University School of Medicine, an equity partner. PBI’s PoZibio®, is a food and dietary supplement ingredient designed to reduce negative side effects linked to increased gut permeability (“leaky gut”). Gutibio™ is a branded medical food product for patients suffering from Inflammatory Bowel Disease, Irritable Bowel Syndrome, and potentially life-long debilitating side effects from chemotherapy and radiation oncology treatments. https://pbihealth.com
About Wake Forest University School of Medicine
Wake Forest University School of Medicine, based in Winston-Salem, North Carolina, is the academic core of Advocate Health, a nationally recognized leader in medical education, research, and clinical care. The School educates nearly 1,900 students, residents, and fellows across programs in medicine, physician assistant studies, academic nursing, and biomedical sciences. It is consistently ranked among the top U.S. medical schools for research and innovation, with more than $400 million in annual research funding.
Media Contact:
Douglas A. Lynch
Partner and Chief Commercial Officer
dlynch@pbihealth.com
+1.609.977.8953
SOURCE: POSTBIOTICS INC.
Source: POSTBIOTICS INC
